Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study

Summary

This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.

Timeline

Start

2026-07

Primary completion

2027-05

Completion

2027-05

Drugs

Indications